Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Novaccess Global Inc XSNX

Healthcare Biotechnology
NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.


OTCQB:XSNX - Post by User

Novaccess Global Inc > Over 300% increase in gross profit Dec 2017 to Dec 2018
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(36)
•••
Comment by virgo85on May 15, 2019 2:25am
99 Views
Post# 29748588

RE:Over 300% increase in gross profit Dec 2017 to Dec 2018

RE:Over 300% increase in gross profit Dec 2017 to Dec 2018Great....let's see Quarterly Gross Profit in Dec 2019..... Ould be another 300% to 600% $450K to $1M.....
jazzist wrote: Quarterly gross profit in Dec 2017: $36,576. Quarterly gross profit in Dec 2018 $151,414 accounting for an approximate 313% increase year over year. I just wanted to highlight this since some of our web brokers aren't updating OTC stocks as well as others. This information comes from the Condensed Statements of Operations for the Three Months Ended December 31, 2018 and 2017.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities